Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and UCL to pioneer research into Parkinson's disease
Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's disease.
Vets to explore the possibilities of future prevention and treatment.

A pioneering study into the causes and progression of Parkinson's disease is to be carried out by the Royal Veterinary College (RVC) in collaboration with University College London (UCL).

The news follows a $7 million grant from Aligning Science Across Parkinson's (ASAP), an initiative that fosters collaboration and resources to better understand the underlying causes of this debilitating disease.

Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's. Specifically, the team will investigate the role of the LRRK2 gene - one of the most common genetic causes of the disease and a priority drug target.

Dr Patrick Lewis, Professor of Neuroscience at the RVC, said: “The Aligning Science Across Parkinson’s foundation grants represents a new way of approaching research into Parkinson’s, with the clear goal of accelerating progress in our understanding of this disorder. It is a real privilege to be involved in this initiative.”

Parkinson's is a progressive brain disorder that causes slowness, stiffness, tremors and walking and balance problems. The condition affects more than 130,000 people in the UK alone, and the only current available treatments help to alleviate symptoms, but not slow progression of the disease.

Professor Jonathan Elliott, vice-principal (Research and Innovation) at the RVC, said: “The RVC is delighted to be part of this large collaborative effort to advance treatments for Parkinson’s Disease. Neurodegenerative conditions significantly impact on the quality of life of our ageing human population in the UK and Professor Lewis’ role in this collaboration is exciting in its potential to uncover new drug targets to slow progressive loss of functioning neurons."

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.